The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Open accessAbstract
The Cancer Genome Atlas Network recently cataloged recurrent genomic abnormalities in glioblastoma multiforme (GBM). We describe a robust gene expression-based molecular classification of GBM into Proneural, Neural, Classical, and Mesenchymal subtypes and integrate multidimensional genomic data to establish patterns of somatic mutations and DNA copy number. Aberrations and gene expression of EGFR, NF1, and PDGFRA/IDH1 each define the Classical, Mesenchymal, and Proneural subtypes, respectively. Gene signatures of normal brain cell types show a strong relationship between subtypes and different neural lineages. Additionally, response to aggressive therapy differs by subtype, with the greatest benefit in the Classical subtype and no benefit in the Proneural subtype. We provide a framework that unifies transcriptomic and genomic dimensions for GBM molecular stratification with important implications for future studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“High-throughput genomic, epigenomic, and transcriptomic profiling of glioblastoma cells revealed three main subtypes harboring distinct molecular and phenotypic landscapes that affect response to the therapy and clinical outcome: mesenchymal, proneural, and classical subtypes.96,97,98,99,100”
From MiR-128-3p – a gray eminence of the human central nervous system (2024) · cites this paper as [96]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although PDGFRA is a frequent target of genomic amplification and gain-of-function mutations in glioblastoma (15%), such alterations are rare in IDH mutant tumors23,24.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although PDGFRA is a frequent target of genomic amplification and gain-of-function mutations in glioblastoma (15%), such alterations are rare in IDH mutant tumors23,24.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nonetheless, IDH mutant gliomas strongly express PDGFRA (Fig. 2b), and share the proneural transcriptional program characteristic of PDGFRA-amplified tumors23,24.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prevalence of p53 mutations differs in the different GBM molecular subtypes (proneural, mesenchymal, neural and classical) (54%, 32%, 21% and 0%, respectively) [15].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [15]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crucially, the levels of miR-128-3p forms can also differ depending on the genetic and molecular background, as they correlated with the glioblastoma subtypes, with the most reduced expression in the most aggressive mesenchymal one.96,113”
From MiR-128-3p – a gray eminence of the human central nervous system (2024) · cites this paper as [96]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, upregulation of PDGFRA, platelet-derived growth factor receptor alpha, is a hallmark of the proneural subtype [15].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [15]
In the citing paper
“While glioblastoma is the most common malignant primary brain tumor26–28, it is still classified as a “rare” disease, as its incidence rate (i.e., 3/100,000 people) is substantially lower than the rare disease definition rate (i.e., <10/100,000 people)24.”
From Federated learning enables big data for rare cancer boundary detection (2022) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Silhouettes: A graphical aid to the interpretation and validation of cluster analysis
Rousseeuw, P. J. (1987) · Journal of Computational and Applied Mathematics · doi:10.1016/0377-0427(87)90125-7 · Cited by 21,392
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F. Z., Miled, S. B., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,785
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
DAVID: Database for Annotation, Visualization, and Integrated Discovery
Dennis, G., Sherman, B. T., Hosack, D. A., Yang, J., Gao, W., Lane, H. C., & Lempicki, R. A. (2003) · Genome Biology · doi:10.1186/gb-2003-4-5-p3 · Cited by 9,327
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature reviews. Cancer · doi:10.1038/nrc822 · Cited by 6,767
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Summaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,837
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922
Self-citation
Cited by
Sorted by citations
Items 301–400 of 1,022
Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives
Seker-Polat, F., Degirmenci, N. P., Solaroğlu, İ., & Onder, T. B. (2022) · Cancers · doi:10.3390/cancers14020443 · Cited by 261
Leveraging models of cell regulation and GWAS data in integrative network-based association studies
Califano, A., Butte, A. J., Friend, S. H., Ideker, T., & Schadt, E. E. (2012) · Nature Genetics · doi:10.1038/ng.2355 · Cited by 260
Integrative Subtype Discovery in Glioblastoma Using iCluster
Shen, R., Mo, Q., Schultz, N. D., Seshan, V., Olshen, A. B., Huse, J. T., Ladanyi, M., & Sander, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035236 · Cited by 261
Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression
Sullivan, J. P., Nahed, B. V., Madden, M. W., Oliveira, S. M., Springer, S. U., Bhere, D., Chi, A. S., Wakimoto, H., Rothenberg, S. M., Sequist, L. V. D., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0471 · Cited by 258
Cancer Stem Cell Hierarchy in Glioblastoma Multiforme
Bradshaw, A., Wickremsekera, A., Tan, S. T., Peng, L., Davis, P. F., & Itinteang, T. (2016) · Frontiers in Surgery · doi:10.3389/fsurg.2016.00021 · Cited by 277
DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in Glioma
Christensen, B. C., Smith, A. A., Zheng, S., Koestler, D. C., Houseman, E. A., Marsit, C. J., Wiemels, J. L., Nelson, H. H., Karagas, M. R., Wrensch, M., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq497 · Cited by 261
Extracellular vesicles and intercellular communication within the nervous system
Zappulli, V., Friis, K. P., Fitzpatrick, Z., Maguire, C. A., & Breakefield, X. O. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81134 · Cited by 262
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Circulating biomarkers in patients with glioblastoma
Bark, J. M., Kulasinghe, A., Chua, B., Day, B. W., & Punyadeera, C. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0603-6 · Cited by 262
Caspase-8: The double-edged sword
Mandal, R., Compte, J., Kostova, I., Becker, S., & Strebhardt, K. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188357 · Cited by 261
Verdugo, E., Puerto, I., & Medina, M. Á. (2022) · 癌症：英文版 · doi:10.1002/cac2.12361 · Cited by 250
Segerman, A., Niklasson, M., Haglund, C., Bergström, T., Jarvius, M., Xie, Y., Westermark, A., Sönmez, D., Hermansson, A., Kastemar, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.11.056 · Cited by 246
Molecular Heterogeneity in Glioblastoma: Potential Clinical Implications
Parker, N., Khong, P., Parkinson, J., Howell, V. M., & Wheeler, H. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00055 · Cited by 263
Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma
Singer, E. A., Judkins, J., Salomonis, N., Matlaf, L., Soteropoulos, P., McAllister, S. D., & Soroceanu, L. (2015) · Cell Death and Disease · doi:10.1038/cddis.2014.566 · Cited by 253
Caudo‐rostral brain spreading of α‐synuclein through vagal connections
Ulusoy, A., Rusconi, R., Pérez‐Revuelta, B. I., Musgrove, R. E., Helwig, M., Winzen‐Reichert, B., & Monte, D. A. D. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302475 · Cited by 254
Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma
Padfield, E., Ellis, H. P., & Kurian, K. M. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00005 · Cited by 257
He, J., Li, C., Ding, L., Huang, Y., Yin, X., Zhang, J., Zhang, J., Yao, C., Liang, M., Pirraco, R. P., et al. (2019) · Advanced Materials · doi:10.1002/adma.201902409 · Cited by 248
Self-citationMaintenance of primary tumor phenotype and genotype in glioblastoma stem cells
Wakimoto, H., Mohapatra, G., Kanai, R., Curry, W. T., Yip, S. S. F., Nitta, M., Patel, A. P., Barnard, Z. R., Stemmer-Rachamimov, A. O., Louis, D. N., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor195 · Cited by 245
Epigenetic encoding, heritability and plasticity of glioma transcriptional cell states
Chaligné, R., Gaiti, F., Silverbush, D., Schiffman, J. S., Weisman, H. R., Kluegel, L., Gritsch, S., Deochand, S. D., Castro, L. N. G., Richman, A. R., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00927-7 · Cited by 247
Mellinghoff, I. K., Lu, M., Wen, P. Y., Taylor, J. W., Maher, E. A., Arrillaga‐Romany, I., Peters, K. B., Ellingson, B. M., Rosenblum, M. K., Chun, S., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02141-2 · Cited by 256
Puget, S., Philippe, C., Bax, D. A., Job, B., Varlet, P., Junier, M., Andreiuolo, F. D. M., Carvalho, D. M., Reis, R., Guerrini‐Rousseau, L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030313 · Cited by 256
NFKBIA Deletion in Glioblastomas
Bredel, M., Scholtens, D. M., Yadav, A. K., Alvarez, A. A., Renfrow, J. J., Chandler, J. P., Yu, I. L. Y., Carro, M. S., Dai, F., Tagge, M. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006312 · Cited by 247
AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma
Chow, R. D.-W., Guzman, C. D., Wang, G., Schmidt, F., Youngblood, M. W., Ye, L., Errami, Y., Dong, M. B., Martinez, M. A. Q., Zhang, S., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4620 · Cited by 240
Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective
Mathur, R., Wang, Q., Schupp, P. G., Nikolić, A., Hilz, S., Hong, C., Grishanina, N. R., Kwok, D. W., Stevers, N. O., Jin, Q., et al. (2024) · Cell · doi:10.1016/j.cell.2023.12.013 · Cited by 262
Non-Stem Cell Origin for Oligodendroglioma
Persson, A. I., Petritsch, C. K., Swartling, F. J., Itsara, M., Sim, F. J., Auvergne, R. M., Goldenberg, D., VandenBerg, S. R., Nguyen, K. N., Yakovenko, S., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.033 · Cited by 246
Emerging Applications of Artificial Intelligence in Neuro-Oncology
Rudie, J. D., Rauschecker, A. M., Bryan, R. N., Davatzikos, C. A., & Mohan, S. (2019) · Radiology · doi:10.1148/radiol.2018181928 · Cited by 247
Ren, Y., Huang, Z., Zhou, L., Xiao, P., Song, J., He, P., Xie, C., Zhou, R., Li, M., Dong, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36707-6 · Cited by 252
Paediatric and adult malignant glioma: close relatives or distant cousins?
Jones, C., Perryman, L., & Hargrave, D. R. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.87 · Cited by 249
Chalise, P., & Fridley, B. L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176278 · Cited by 239
Fedele, M., Cerchia, L., Pegoraro, S., Sgarra, R., & Manfioletti, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112746 · Cited by 229
Macrophages and microglia: the cerberus of glioblastoma
Buonfiglioli, A., & Hambardzumyan, D. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01156-z · Cited by 254
Squatrito, M., Brennan, C., Helmy, K. Y., Huse, J. T., Petrini, J. H. J., & Holland, E. C. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.034 · Cited by 242
Self-citationMetzincin proteases and their inhibitors: foes or friends in nervous system physiology?
Rivera, S., Khrestchatisky, M., Kaczmarek, L., Rosenberg, G. A., & Jaworski, D. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3467-10.2010 · Cited by 223
PDGF receptor signaling networks in normal and cancer cells
Demoulin, J., & Essaghir, A. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.03.003 · Cited by 238
Yan, D., Kowal, J., Akkari, L., Schuhmacher, A. J., Huse, J. T., West, B. L., & Joyce, J. A. (2017) · Oncogene · doi:10.1038/onc.2017.261 · Cited by 238
Tissue Force Programs Cell Fate and Tumor Aggression
Northey, J. J., Przybyla, L., & Weaver, V. M. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0733 · Cited by 242
Single-cell transcriptome analysis of lineage diversity in high-grade glioma
Yuan, J., Levitin, H. M., Frattini, V., Bush, E. C., Boyett, D. M., Samanamud, J. L., Ceccarelli, M., Dovas, A., Zanazzi, G. J., Canoll, P., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0567-9 · Cited by 235
Joo, K. M., Kim, J., Jin, J., Kim, M., Seol, H. J., Muradov, J. M., Yang, H., Choi, Y., Park, W., Kong, D., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2012.12.013 · Cited by 239
Simultaneous Identification of Multiple Driver Pathways in Cancer
Leiserson, M. D. M., Blokh, D., Sharan, R., & Raphael, B. J. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003054 · Cited by 240
Novel Oncogenic PDGFRA Mutations in Pediatric High-Grade Gliomas
Paugh, B. S., Zhu, X., Qu, C., Endersby, R., Diaz, A. K., Zhang, J., Bax, D. A., Carvalho, D., Reis, R. M., Onar-Thomas, A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1491 · Cited by 235
Jain, R., Poisson, L., Gutman, D. A., Scarpace, L. M., Hwang, S. N., Holder, C. A., Wintermark, M., Rao, A. U. K., Colen, R. R., Kirby, J., et al. (2014) · Radiology · doi:10.1148/radiol.14131691 · Cited by 238
Rodon, J. A., Carducci, M. A., Sepúlveda-Sánchez, J. M., Azaro, A., Calvo, E., Seoane, J., Braña, I., Sicart, E., Gueorguieva, I., Cleverly, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1380 · Cited by 239
Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target
Jackson, M., Hassiotou, F., & Nowak, A. K. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu243 · Cited by 246
The Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
Kahrilas, P. J., & Boeckxstaens, G. E. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 236
Predicting clinical outcomes from large scale cancer genomic profiles with deep survival models
Yousefi, S., Amrollahi, F., Amgad, M. T., Dong, C., Lewis, J. E., Song, C., Gutman, D. A., Halani, S. H., Vega, J. E. V., Brat, D. J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11817-6 · Cited by 243
Molecular subclassification of diffuse gliomas: Seeing order in the chaos
Huse, J. T., PHILLIPS, H. S., & Brennan, C. (2011) · Glia · doi:10.1002/glia.21165 · Cited by 237
Self-citationMcellin, B. M., Camacho, C. V., Mukherjee, B., Hahm, B., Tomimatsu, N., Bachoo, R. M., & Burma, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4295 · Cited by 234
Recurrent MET fusion genes represent a drug target in pediatric glioblastoma
Bender, S., Gröbner, S. N., Pfaff, E., Kool, M., Northcott, P. A., Sturm, D., Worst, B. C., Pfister, S. M., Jones, D. T. W., van Tilburg, C. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4204 · Cited by 234
Kahlert, U. D., Maciaczyk, D., Doostkam, S., Orr, B. A., Simons, B. W., Bogiel, T., Reithmeier, T., Prinz, M., Schubert, J., Niedermann, G., et al. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.05.024 · Cited by 231
Safa, A. R., Saadatzadeh, M. R., Cohen‐Gadol, A., Pollok, K. E., & Bijangi‐Vishehsaraei, K. (2015) · Genes & Diseases · doi:10.1016/j.gendis.2015.02.001 · Cited by 230
Lisi, L., Ciotti, G. M. P., Braun, D. J., Kalinin, S., Currò, D., Russo, C. D., Coli, A., Mangiola, A., Anile, C., Feinstein, D. L., et al. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.02.076 · Cited by 228
Cooper, L., Gutman, D. A., Chisolm, C., Appin, C., Kong, J., Rong, Y., Kurç, T., Meir, E. G. V., Saltz, J. H., Moreno, C. S., et al. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.01.040 · Cited by 235
Toward precision medicine in glioblastoma: the promise and the challenges
Prados, M. D., Byron, S. A., Tran, N. L., Phillips, J. J., Molinaro, A. M., Ligon, K. L., Wen, P. Y., Kuhn, J. G., Mellinghoff, I. K., de Groot, J., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov031 · Cited by 231
Glioblastoma in England: 2007–2011
Brodbelt, A. R., Greenberg, D. C., Winters, T., Williams, M., Vernon, S., & Collins, V. P. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2014.12.014 · Cited by 228
Immune Heterogeneity of Glioblastoma Subtypes: Extrapolation from the Cancer Genome Atlas
Doucette, T. A., Rao, G., Rao, A. U. K., Shen, L., Aldape, K., Wei, J., Dziurzynski, K., Gilbert, M. R., & Heimberger, A. B. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0028 · Cited by 249
Combination therapy to checkmate Glioblastoma: clinical challenges and advances
Ghosh, D., Nandi, S., & Bhattacharjee, S. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0211-8 · Cited by 233
Zhang, J., Han, L., Bao, Z., Wang, Y., Chen, L., Yan, W., Yu, S., Pu, P., Liu, N., You, Y., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not131 · Cited by 226
Molecular and Genomic Alterations in Glioblastoma Multiforme
Crespo, I., Vital, A. L., Gonzalez-Tablas, M., Patino, M. D. C., Otero, A., Lopes, M. C., de Oliveira, C., Domingues, P., Orfao, A., & Tabernero, M. D. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.02.023 · Cited by 225
Comparing the performance of biomedical clustering methods
Wiwie, C., Baumbach, J., & Röttger, R. (2015) · Nature Methods · doi:10.1038/nmeth.3583 · Cited by 223
Hossain, A., Gumin, J., Gao, F., Figueroa, J. M., Shinojima, N., Takezaki, T., Priebe, W., Villarreal, D. D., Kang, S., Joyce, C., et al. (2015) · Stem Cells · doi:10.1002/stem.2053 · Cited by 227
The cellular origin for malignant glioma and prospects for clinical advancements
Zong, H., Verhaak, R. G. W., & Canoll, P. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.30 · Cited by 234
Self-citationEGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise
Westphal, M., Maire, C. L., & Lamszus, K. (2017) · CNS Drugs · doi:10.1007/s40263-017-0456-6 · Cited by 233
Glioblastoma: Microenvironment and Niche Concept
Schiffer, D., Annovazzi, L., Casalone, C., Corona, C., & Mellai, M. (2018) · Cancers · doi:10.3390/cancers11010005 · Cited by 225
DNA methylation in glioblastoma: impact on gene expression and clinical outcome
Etcheverry, A., Aubry, M., de Tayrac, M., Vauléon, É., Boniface, R., Guénot, F., Saïkali, S., Hamlat, A., Riffaud, L., Meneï, P., et al. (2010) · BMC Genomics · doi:10.1186/1471-2164-11-701 · Cited by 221
Turkalp, Z. T., Karamchandani, J., & Das, S. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1205 · Cited by 222
Dihydropyrimidine Accumulation Is Required for the Epithelial-Mesenchymal Transition
Shaul, Y. D., Freinkman, E., Comb, W. C., Cantor, J. R., Tam, W. L., Thiru, P., Kim, D., Kanarek, N., Pacold, M. E., Chen, W. W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.07.032 · Cited by 223
Cancer Stem Cells: Significance in Origin, Pathogenesis and Treatment of Glioblastoma
Biserova, K., Jakovļevs, A., Uljanovs, R., & Štrumfa, I. (2021) · Cells · doi:10.3390/cells10030621 · Cited by 239
Phenotypic Plasticity of Invasive Edge Glioma Stem-like Cells in Response to Ionizing Radiation
Minata, M., Audia, A., Shi, J., Lu, S., Bernstock, J. D., Pavlyukov, M. S., Das, A., Kim, S.-H., Shin, Y. J., Lee, Y., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.076 · Cited by 222
Hallmarks of cancer—the new testament
Senga, S. S., & Grose, R. P. (2021) · Open Biology · doi:10.1098/rsob.200358 · Cited by 245
miR-182 integrates apoptosis, growth, and differentiation programs in glioblastomaPreprint
Kouri, F. M., Hurley, L., Daniel, W. L., Day, E. S., Hua, Y., Hao, L., Peng, C., Merkel, T. J., Queisser, M. A., Ritner, C., et al. (2015) · Genes & Development · doi:10.1101/gad.257394.114 · Cited by 226
Self-citationBinda, E., Visioli, A., Giani, F., Lamorte, G., Copetti, M., Pitter, K. L., Huse, J. T., Cajola, L., Zanetti, N., DiMeco, F., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.11.005 · Cited by 225
Adult Lineage-Restricted CNS Progenitors Specify Distinct Glioblastoma Subtypes
Llaguno, S. R. A., Wang, Z., Sun, D., Chen, J., Xu, J., Kim, E., Hatanpaa, K. J., Raisanen, J. M., Burns, D. K., Johnson, J. E. B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.007 · Cited by 231
Epithelial-to-mesenchymal(-like) transition as a relevant molecular event in malignant gliomas
Kahlert, U. D., Nikkhah, G., & Maciaczyk, J. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.12.010 · Cited by 228
Simultaneous Multiplexed Measurement of RNA and Proteins in Single Cells
Darmanis, S., Gallant, C. J., Marinescu, V. D., Niklasson, M., Segerman, A., Flamourakis, G., Fredriksson, S., Assarsson, E., Lundberg, M., Nelander, S., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.021 · Cited by 219
EphA3 Maintains Tumorigenicity and Is a Therapeutic Target in Glioblastoma Multiforme
Day, B. W., Stringer, B. W., Al‐Ejeh, F., Ting, M. J., Wilson, J., Ensbey, K. S., Jamieson, P. R., Bruce, Z. C., Lim, Y. C., Offenhäuser, C., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.007 · Cited by 213
Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence
Turcan, Ş., Makarov, V., Taranda, J., Wang, Y., Fabius, A. W. M., Wu, W., Zheng, Y., El-Amine, N., Haddock, S., Nanjangud, G. J., et al. (2017) · Nature Genetics · doi:10.1038/s41588-017-0001-z · Cited by 222
Self-citationAn integrative view on sex differences in brain tumors
Sun, T., Plutynski, A., Ward, S., & Rubin, J. B. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1930-2 · Cited by 229
Iser, I. C., Pereira, M. B., Lenz, G., & Wink, M. R. (2016) · Medicinal Research Reviews · doi:10.1002/med.21408 · Cited by 221
Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches
Uddin, M. S., Mamun, A. A., Alghamdi, B. S. A., Tewari, D., Jeandet, P., Sarwar, M. S., & Ashraf, G. M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.015 · Cited by 224
ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation
Biddlestone-Thorpe, L., Sajjad, M., Rosenberg, E., Beckta, J. M., Valerie, N. C. K., Tokarz, M. E., Adams, B. R., Wagner, A. F., Khalil, A. A., Gilfor, D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3408 · Cited by 219
Integrative methods for analyzing big data in precision medicine
Gligorijević, V., Malod‐Dognin, N., & Pržulj, N. (2015) · PROTEOMICS · doi:10.1002/pmic.201500396 · Cited by 226
PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomasPreprint
Ozawa, T., Brennan, C., Wang, L., Squatrito, M., Sasayama, T., Nakada, M., Huse, J. T., Pedraza, A. M., Utsuki, S., Yasui, Y., et al. (2010) · Genes & Development · doi:10.1101/gad.1972310 · Cited by 225
Self-citationThe REMBRANDT study, a large collection of genomic data from brain cancer patients
Gusev, Y., Bhuvaneshwar, K., Song, L., Zenklusen, J.-C., Fine, H. A., & Madhavan, S. (2018) · Scientific Data · doi:10.1038/sdata.2018.158 · Cited by 211
Intratumoral Heterogeneity of the Epigenome
Mazor, T., Pankov, A., Song, J. S., & Costello, J. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.009 · Cited by 217
Comparison of glioblastoma (GBM) molecular classification methods
Lee, E., Yong, R. L. M., Paddison, P. J., & Zhu, J. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.07.006 · Cited by 219
PRMT5 inhibition disrupts splicing and stemness in glioblastoma
Sachamitr, P., Ho, J. C., Ciamponi, F. E., Ba-Alawi, W., Coutinho, F. J., Guilhamon, P., Kushida, M. M., Cavalli, F. M. G., Lee, L., Rastegar, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21204-5 · Cited by 227
CAR T cells for brain tumors: Lessons learned and road ahead
Akhavan, D., Alizadeh, D., Wang, D., Weist, M. R., Shepphird, J. K., & Brown, C. E. (2019) · Immunological Reviews · doi:10.1111/imr.12773 · Cited by 217
TP53 gain-of-function mutation promotes inflammation in glioblastoma
Ham, S. W., Jeon, H.-Y., Jin, X., Kim, E.-J., Kim, J.-K., Shin, Y. J., Lee, Y., Kim, S. H., Lee, S. Y., Seo, S., et al. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0126-3 · Cited by 213
Nanomaterials for Cancer Precision Medicine
Wang, Y., Sun, S., Zhang, Z., & Shi, D. (2018) · Advanced Materials · doi:10.1002/adma.201705660 · Cited by 213
Tumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology
Becker, A. P., Sells, B. E., Haque, S., & Chakravarti, A. (2021) · Cancers · doi:10.3390/cancers13040761 · Cited by 234
Statistical Significance for Hierarchical Clustering
Kimes, P. K., Liu, Y., Hayes, D. N., & Marron, J. S. (2017) · Biometrics · doi:10.1111/biom.12647 · Cited by 213
Self-citationLiu, I., Jiang, L., Samuelsson, E. R., Salas, S. M., Beck, A., Hack, O. A., Jeong, D., Shaw, M. L., Englinger, B., LaBelle, J. J., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01236-3 · Cited by 225
Davatzikos, C., Rathore, S., Bakas, S., Pati, S., Bergman, M., Kalarot, R., Sridharan, P., Gastounioti, A., Jahani, N., Cohen, E., et al. (2018) · Journal of Medical Imaging · doi:10.1117/1.jmi.5.1.011018 · Cited by 204
CD70, a novel target of CAR T-cell therapy for gliomas
Jin, L., Ge, H., Long, Y., Yang, C., Chang, Y. E., Mu, L., Sayour, E. J., Leon, G. D., Wang, Q. J., Yang, J. C., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox116 · Cited by 215
Immune landscapes associated with different glioblastoma molecular subtypes
Martinez‐Lage, M., Lynch, T. M., Bi, Y., Cocito, C., Way, G. P., Pal, S., Haller, J., Yan, R., Ziober, A. F., Nguyen, A. T., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0803-6 · Cited by 211
CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer
Leiserson, M. D. M., Wu, H.-T., Vandin, F., & Raphael, B. J. (2015) · Genome biology · doi:10.1186/s13059-015-0700-7 · Cited by 205
Huang, J., Jiang, G., Song, Q., Gu, X. Q., Meng, H., Wang, X.-L., Song, H., Chen, L., Lin, Y., Jiang, D. M., et al. (2017) · Nature Communications · doi:10.1038/ncomms15144 · Cited by 212
Stringer, B. W., Day, B. W., D’Souza, R. C. J., Jamieson, P. R., Ensbey, K. S., Bruce, Z. C., Lim, Y. C., Goasdoué, K., Offenhäuser, C., Akgül, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41277-z · Cited by 213
Weng, Q., Wang, J., Wang, J., He, D., Cheng, Z., Zhang, F., Verma, R., Xu, L., Dong, X., Liao, Y., et al. (2019) · Cell stem cell · doi:10.1016/j.stem.2019.03.006 · Cited by 206
Karabeber, H., Huang, R., Iacono, P., Samii, J. M., Pitter, K. L., Holland, E. C., & Kircher, M. F. (2014) · ACS Nano · doi:10.1021/nn503948b · Cited by 212
Metadata
- Authors
- Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., Alexe, G., Lawrence, M., O'Kelly, M., Tamayo, P., Weir, B. A., Gabriel, S., Winckler, W., Gupta, S., Jakkula, L., Feiler, H. S., Hodgson, J. G., James, C. D., Sarkaria, J. N., Brennan, C., Kahn, A., Spellman, P. T., Wilson, R. K., Speed, T. P., Gray, J. W., Meyerson, M., Getz, G., Perou, C. M., & Hayes, D. N.
- Affiliations
- Broad Institute (US)
- University of North Carolina at Chapel Hill (US)
- University of California, Berkeley (US)
- Washington University in St. Louis (US)
- Lawrence Berkeley National Laboratory (US)
- University of California, San Francisco (US)
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- SRA International (United States) (US)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Corresponding author
- Hayes, D. Neil
- ORCID
- Verhaak, Roel G.W.
- Hoadley, Katherine A.
- Purdom, Elizabeth
- Wang, Victoria
- Qi, Yuan
- Wilkerson, Matthew D.
- Miller, C. Ryan
- Ding, Li
- Golub, Todd
- Mesirov, Jill P.
- Lawrence, Michael
- Tamayo, Pablo
- Gabriel, Stacey
- Winckler, Wendy
- Gupta, Supriya
- Feiler, Heidi S.
- Hodgson, J. Graeme
- James, C. David
- Sarkaria, Jann N.
- Brennan, Cameron
- Spellman, Paul T.
- Wilson, Richard K.
- Speed, Terence P.
- Gray, Joe W.
- Meyerson, Matthew
- Getz, Gad
- Perou, Charles M.
- Hayes, D. Neil
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 17
- Issue
- 1
- Pages
- 98-110
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC2818769
- OpenAlex
- W2161289668
- Cited by
- 7,575
- References
- 52
- Citations by year
- 2026: 312 · 2025: 399 · 2024: 451 · 2023: 551 · 2022: 523 · 2021: 697 · 2020: 593 · 2019: 493 · 2018: 482 · 2017: 522 · 2016: 502 · 2015: 455 · 2014: 459 · 2013: 406 · 2012: 379
- FWCI
- 159.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Energy
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273)
- National Cancer Institute (CA097257, L30 CA104183, U24CA126554, R01CA127716, CA108961, U24CA126546, U24CA126543, U24CA126563, U24CA126544, U24CA143867, U24CA143848, P50CA108961, U24CA126551, CA127716, P50 CA 58223, U24CA126561, P50CA058223, P50CA097257)
- National Institute of Neurological Disorders and Stroke (R01NS049720, NS49720)
- National Institute of Environmental Health Sciences (F30ES019449)
- National Center for Research Resources (RR023248, K12RR023248, UL1RR024992)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- glioblastoma, molecular subtypes, proneural subtype, mesenchymal subtype, classical subtype, PDGFRA, IDH1, EGFR, neurofibromatosis type 1, somatic mutations, gene expression signatures, neural lineage, treatment response, molecular stratification
- MeSH terms
- Adult, Aged, Brain Neoplasms, DNA Mutational Analysis, Factor Analysis, Statistical, Glioblastoma, Humans, Isocitrate Dehydrogenase, Middle Aged, Mutation, Neurofibromatosis 1, Prognosis, Gene Expression, Gene Dosage, Oligonucleotide Array Sequence Analysis, Receptor, Platelet-Derived Growth Factor alpha, Gene Expression Profiling, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
